EIKN · Eikon Therapeutics, Inc. · Documents

$5.90 +0.06 (+1.03%) At close · Nov 6

Russell 2000 member Rebalance outlook locked

Market Cap

$319.57M

54.17M

Volume · Nov 6 402.39K Avg daily vol (3M) 576.61K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report Ended Dec 31, 2025 10-K filed Mar 30, 2026 Quarterly report FY2026 Q2 Net loss $88.41M 10-Q filed Aug 13, 2026 Latest results Financial results 8-K filed Aug 13, 2026

2026

Oct 26

Current report 8-K

Regulation FD disclosure, Other events

Eikon Therapeutics reported updated TeLuRide-005 results for EIK1001 plus pembrolizumab and chemotherapy in stage 4 NSCLC: 63.1% ORR, 89.2% DCR, and 48.6% Grade 3 or higher TRAEs; TeLuRide-008 is enrolling, with dose selection planned for the second half of 2027.

Oct 23

Current report 8-K

Regulation FD disclosure, Other events

Eikon Therapeutics presented EIK1003, EIK1004 and EIK1005 clinical data at the 2026 ESMO Congress. EIK1003 combination ORRs were 20.8% and 26.4%, EIK1004 monotherapy ORR was 12.1%, and an EIK1005 combination participant achieved a partial response.

Sep 15

Investor event

Morgan Stanley 24th Annual Global Healthcare Conference AI summary on its way

Aug 14

Current report 8-K Events of Aug 13

Regulation FD disclosure AI summary on its way

Aug 13

Current report 8-K

Financial results AI summary on its way

Aug 13

Quarterly report 10-Q FY2026 Q2, ended Jun 30

Quarterly report for FY2026 Q2 AI summary on its way

Net loss $88.41M Diluted EPS -$1.63

Aug 3

Current report 8-K Events of Jul 31

Director or officer change, or executive pay AI summary on its way

Jun 10

Current report 8-K Events of Jun 5

Director or officer change, or executive pay AI summary on its way

Jun 1

Current report 8-K Events of May 30

Regulation FD disclosure, Other events AI summary on its way

May 11

Current report 8-K

Financial results, Regulation FD disclosure AI summary on its way

May 11

Quarterly report 10-Q FY2026 Q1, ended Mar 31

Quarterly report for FY2026 Q1 AI summary on its way

Net loss $82.96M Diluted EPS -$2.46

Mar 30

Current report 8-K

Financial results AI summary on its way

Mar 30

Annual report 10-K Ended Dec 31

Annual report for the period ended Dec 31, 2025 AI summary on its way

Feb 6

Current report 8-K

Charter or bylaw amendment, or fiscal year change AI summary on its way

Jan 28

Registration statement S-1/A

Registration statement AI summary on its way

Jan 9

Registration statement S-1

Registration statement AI summary on its way

Showing 1–16 of 16 documents

Key facts CIK 1861123 CUSIP 282564103 13F (30d) 28 filings 28 filers Visit website Investor relations